Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.
Keller PJ, Adams EJ, Wu R, Côté A, Arora S, Cantone N, Meyer R, Mertz JA, Gehling V, Cui J, Stuckey JI, Khanna A, Zhao F, Chen Z, Yu Z, Cummings R, Taimi M, Lakhani NJ, Rasco DW, Gutierrez M, Duska L, Devitt M, Rippley R, Levell J, Truong J, Wang J, Sun K, Trojer P.
Keller PJ, et al. Among authors: adams ej.
Cancer Res. 2024 Jun 4. doi: 10.1158/0008-5472.CAN-24-0398. Online ahead of print.
Cancer Res. 2024.
PMID: 38833522